The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BackgroundPD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for adv...

Полное описание

Библиографические подробности

Главные авторы:	Dongxu Wang, Xu Yang, Junyu Long, Jianzhen Lin, Jinzhu Mao, Fucun Xie, Yunchao Wang, Yanyu Wang, Ziyu Xun, Yi Bai, Xiaobo Yang, Mei Guan, Jie Pan, Samuel Seery, Xinting Sang, Haitao Zhao
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2021-04-01
Серии:	Frontiers in Oncology
Предметы:	apatinib camrelizumab (SHR-1210) advanced biliary tract cancer combination therapy PD-1/L1 blockade target therapy
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2021.646979/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!